A carregar...
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects
BACKGROUND: Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C virus treatment. METHODS: To assess drug interactions between the HIV integrase strand transfer inhibitor dolutegravir (DTG) and DCV, subjects were randomized into 1 of 2 sequences in an...
Na minha lista:
| Publicado no: | BMC Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4957413/ https://ncbi.nlm.nih.gov/pubmed/27450277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-1629-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|